The most influential guidelines recommend CDK4/6 inhibitors as the first- or second-line therapy for all postmenopausal women with advanced BC, independent of previous adjuvant therapy, number and site of metastases, performance status, and histology (excluding visceral crises) [21]. Here, CDK4 is linked to breast cancer.